Lugade, Amit

Local Radiation Therapy of B16 Melanoma Tumors Increases the Generation of Tumor Antigen-Specific Effector Cells That Traffic to the Tumor

Lugade, A. A., Moran, J. P., Gerber, S. A., Rose, R. C., Frelinger, J. G., & Lord, E. M. (2005) · The Journal of Immunology

Immunotherapy and Immune ResponsesCancer Immunotherapy and Biomarkers

Cited by 966

Key parameters of tumor epitope immunogenicity revealed through a consortium approach improve neoantigen prediction

Wells, D. K., van Buuren, M. M., Dang, K. K., Hubbard-Lucey, V. M., Sheehan, K. C. F., Campbell, K. M., Lamb, A., Ward, J. P., Sidney, J., Blazquez, A. B., et al. (2020) · Cell

vaccines and immunoinformatics approachesCancer Immunotherapy and Biomarkers

Cited by 538

Sorafenib: a clinical and pharmacologic review

Iyer, R., Fetterly, G., Lugade, A., & Thanavala, Y. (2010) · Expert Opinion on Pharmacotherapy

Hepatocellular Carcinoma Treatment and PrognosisAngiogenesis and VEGF in Cancer

Cited by 169

A prime/boost vaccine platform efficiently identifies CD27 agonism and depletion of myeloid-derived suppressor cells as therapies that rationally combine with checkpoint blockade in ovarian cancer

McGray, A. J. R., Eppolito, C., Miliotto, A., Singel, K. L., Stephenson, K., Lugade, A., Segal, B. H., Keler, T., Webster, G., Lichty, B., et al. (2021) · Cancer Immunology, Immunotherapy

Cancer Immunotherapy and BiomarkersImmunotherapy and Immune Responses

Cited by 12